Limitations of in vitro assessments of the drug interaction potential of botanical supplements

Planta Medica

Volumn 78, Issue 13, 2012, Pages 1421-1427

  Markowitz, John S ^a   Zhu, Hao Jie ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

botanical; in vitro; in vivo; interaction; metabolism

Indexed keywords

ASTEMIZOLE; CISAPRIDE; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 3A; EXCIPIENT; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A9; GLYCOPROTEIN P; INDINAVIR; LYCOPENE; METHYLPHENIDATE; MIBEFRADIL; MIDAZOLAM; ORGANIC SOLVENT; OSELTAMIVIR; SILIBININ; SILYBUM MARIANUM EXTRACT; SILYMARIN; TERFENADINE;

ANTIOXIDANT ACTIVITY; BOTANICAL DRUG INTERACTION; CELL STRAIN CACO 2; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG INTERACTION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME SUBSTRATE; GENETIC VARIABILITY; HUMAN; IN VITRO STUDY; LIVER PROTECTION; NONHUMAN; PHYTOCHEMISTRY; REVIEW;

CELL CULTURE TECHNIQUES; CELL LINE; CHEMISTRY, PHARMACEUTICAL; DIETARY SUPPLEMENTS; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; HERB-DRUG INTERACTIONS; HUMANS; LIVER; PHARMACOKINETICS; PLANT PREPARATIONS; REAGENT KITS, DIAGNOSTIC;

EID: 84866082324     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0032-1315025     Document Type: Review

References (46)

1. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod: 2007; 70 461 477
2. Bailey RL, Gahche JJ, Lentino CV, Dwyer JT, Engel JS, Thomas PR, Betz JM, Sempos CT, Picciano MF. Dietary supplement use in the United States, 2003-2006. J Nutr: 2011; 141 261 266
3. Markowitz JS, von Moltke LL, Donovan JL. Predicting interactions between conventional medications and botanical products on the basis of in vitro investigations. Mol Nutr Food Res: 2008; 52 747 754
4. Greenblatt DJ, von Moltke LL, Harmatz JS, Chen G, Weemhoff JL, Jen C, Kelley CJ, LeDuc BW, Zinny MA. Time course of recovery of cytochrome p 450 3A function after single doses of grapefruit juice. Clin Pharmacol Ther: 2003; 74 121 129
5. Li P, Callery PS, Gan LS, Balani SK. Esterase inhibition by grapefruit juice flavonoids leading to a new drug interaction. Drug Metab Dispos: 2007; 35 1203 1208
6. Li P, Callery PS, Gan LS, Balani SK. Esterase inhibition attribute of grapefruit juice leading to a new drug interaction. Drug Metab Dispos: 2007; 35 1023 1031
7. Liu R, Tam TW, Mao J, Saleem A, Krantis A, Arnason JT, Foster BC. The effect of natural health products and traditional medicines on the activity of human hepatic microsomal-mediated metabolism of oseltamivir. J Pharm Pharm Sci: 2010; 13 43 55
8. Rodriguez-Fragoso L, Martinez-Arismendi JL, Orozco-Bustos D, Reyes-Esparza J, Torres E, Burchiel SW. Potential risks resulting from fruit/vegetable-drug interactions: effects on drug-metabolizing enzymes and drug transporters. J Food Sci: 2011; 76 R112 R124
9. Ioannides C. Effect of diet and nutrition on the expression of cytochromes P450. Xenobiotica: 1999; 29 109 154
10. Chavez ML, Jordan MA, Chavez PI. Evidence-based drug-herbal interactions. Life Sci: 2006; 78 2146 2157
11. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St Johns wort. Lancet: 2000; 355 547 548
12. Mannel M. Drug interactions with St Johns wort: mechanisms and clinical implications. Drug Saf: 2004; 27 773 797
13. von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI. In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol: 1998; 55 113 222
14. Pelkonen O, Turpeinen M, Uusitalo J, Rautio A, Raunio H. Prediction of drug metabolism and interactions on the basis of in vitro investigations. J Basic Clin Pharmacol Toxicol: 2005; 96 167 175
15. Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov: 2005; 4 825 833
16. Dürr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K. St Johns Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther: 2000; 68 598 604
17. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet: 2003; 42 59 98
18. Li Y, Revalde JL, Reid G, Paxton JW. Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer. Drug Metab Rev: 2010; 42 590 611
19. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. Acute heart transplant rejection due to Saint Johns wort. Lancet: 2000; 355 548 549
20. Alfaro CL. Emerging role of drug interaction studies in drug development: the good, the bad, and the unknown. Psychopharmacol Bull: 2001; 35 80 93
21. Masimirembwa CM, Thompson R, Andersson TB. In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery. Comb Chem High Throughput Screen: 2001; 4 245 263
22. Kosugi Y, Hirabayashi H, Igari T, Fujioka Y, Hara Y, Okuda T, Moriwaki T. Evaluation of cytochrome P450-mediated drug-drug interactions based on the strategies recommended by regulatory authorities. Xenobiotica: 2012; 42 127 138
23. Gurley BJ, Hagan DW. editors. Herbal and dietary supplement interactions with drugs. Boca Raton CRC Press: 2003
24. van Breemen RB, Fong HHS, Farnsworth NR. Ensuring the safety of botanical dietary supplements. Am J Clin Nutr: 2008; 509S 513S
25. Hedman A, Meijer DK. The stereoisomers quinine and quinidine exhibit a marked stereoselectivity in the inhibition of hepatobiliary transport of cardiac glycosides. J Hepatol: 1998; 28 240 249
26. Ai C, Li Y, Wang Y, Chen Y, Yang L. Insight into the effects of chiral isomers quinidine and quinine on CYP2D6 inhibition. Bioorg Med Chem Lett: 2009; 19 803 806
27. Kroon PA, Clifford MN, Crozier A, Day AJ, Donovan JL, Manach C, Williamson G. How should we assess the effects of exposure to dietary polyphenols in vitro ? Am J Clin Nutr: 2004; 80 15 21
28. Gurley BJ. Emerging technologies for improving phytochemical bioavailability: benefits and risks. Clin Pharmacol Ther: 2011; 89 915 919
29. Donovan JL, DeVane CL, Boulton D, Dodd S, Markowitz JS. Dietary levels of quinine in tonic water do not inhibit CYP2D6 in vivo. Food Chem Toxicol: 2003; 41 1199 1201
30. Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos: 2004; 32 587 594
31. Venkataramanan R, Ramachandran V, Komoroski BJ, Zhang S, Schiff PL, Strom SC. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos: 2000; 28 1270 1273
32. Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, Böcker RH, Beckurts KT, Lang W, Hunz M, Fuhr U. Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol: 2000; 86 250 256
33. Zuber R, Modriansky M, Dvorák Z, Rohovsk P, Ulrichová J, Simánek V, Anzenbacher P. Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities. Phytother Res: 2002; 16 632 638
34. Zhang S, Morris ME. Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm Res: 2003; 20 1184 1191
35. Zhang S, Morris ME. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther: 2003; 304 1258 1267
36. Zhao J, Agarwal R. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. Carcinogenesis: 1999; 20 2101 2108
37. Piscitelli SC, Formentini E, Burstein AH, Alfaro R, Jagannatha S, Falloon J. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy: 2002; 22 551 556
38. DiCenzo R, Shelton M, Jordan K, Koval C, Forrest A, Reichman R, Morse G. Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy: 2003; 23 866 870
39. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, Khan IA, Edwards DJ, Shah A. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther: 2004; 76 428 440
40. Venkataramanan R, Komoroski B, Strom S. In vitro and in vivo assessment of herb drug interactions. Life Sci: 2006; 78 2105 2115
41. Wu JW, Lin LC, Hung SC, Chi CW, Tsai TH. Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application. J Pharm Biomed Anal: 2007; 45 635 641
42. Wen Z, Dumas TE, Schrieber SJ, Hawke RL, Fried MW, Smith PC. Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos: 2008; 36 65 72
43. Imai T, Imoto M, Sakamoto H, Hashimoto M. Identification of esterases expressed in Caco-2 cells and effects of their hydrolyzing activity in predicting human intestinal absorption. Drug Metab Dispos: 2005; 33 1185 1190
44. Pifferi G, Restani P. The safety of pharmaceutical excipients. Farmaco: 2003; 58 541 550
45. Chen ML, Straughn AB, Sadrieh N, Meyer M, Faustino PJ, Ciavarella AB, Meibohm B, Yates CR, Hussain AS. A modern view of excipient effects on bioequivalence: case study of sorbitol. Pharm Res: 2007; 24 73 80
46. Xin GZ, Qi LW, Shi ZQ, Li P, Hao HP, Wang GJ, Shang J. Strategies for integral metabolism profile of multiple compounds in herbal medicines: pharmacokinetics, metabolites characterization and metabolic interactions. Curr Drug Metab 2011; 12: 809-817